|
|
|
|
|
03.05.26 - 19:15
|
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers (Business Wire)
|
|
|
Deal builds upon UCB's position as a leader in immunology innovation and expands capabilities in next-generation biologics with potential for immune reset
Candid's lead asset, cizutamig, a bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, is currently in multiple phase 1 clinical studies across various autoimmune diseases
Total transaction value of up to US $2.2 billion consisting of US $2 billion in upfront payments plus up to US $200 million in potential future milestone payments
SAN DIEGO--(BUSINESS WIRE)--UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs). This transaction supports UCB's ambition to bring differentiated solutions to people with severe immune-mediated diseases by focusing on areas o...
|
|
|
29.04.26 - 23:57
|
XETR: DIVIDEND/INTEREST INFORMATION - 04.05.2026 - BE0003739530 (XETRA)
|
|
|
Das Instrument UNC BE0003739530 UCB S.A. EQUITY wird cum Dividende/Zinsen gehandelt am 30.04.2026 und ex Dividende/Zinsen am 04.05.2026
The instrument UNC BE0003739530 UCB S.A. EQUITY has its pre-dividend/interest day on 30.04.2026 and its ex-dividend/interest day on 04.05.2026...
|
|
|
|
|
20.04.26 - 12:24
|
UCB to purchase Neurona and NRTX-1001 for $1.15bn (PBR)
|
|
|
The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. Subject to customary conditions and anti-trust clearance, the transaction is
The post UCB to purchase Neurona and NRTX-1001 for $1.15bn appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.03.26 - 21:06
|
KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance (Business Wire)
|
|
|
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company also initiated guidance for the full year 2026.
Recent Highlights
Fourth quarter 2025 net revenues grew 23% to $10.9 million; Full year 2025 net revenues grew 22% to $41.1 million
Full year 2025 gross profit grew 20% to $25.6 million with gross margin of 62.3%
Full year 2025 net loss of ($2.6) million, a 57% improvement over the prior year and a 124% increase in positive adjusted EBITDA to $0.6 million
Ending cash balance of $8.9 million, representing annual cash usage of $0.7 million, a 63% improvement versus the prior year
Received 510(k) clearance for UCB RYSTIGGO®, further expanding the KORU Medical pla...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
